Ikena Oncology (IKNA)
(Delayed Data from NSDQ)
$1.67 USD
-0.01 (-0.60%)
Updated Jul 24, 2024 04:00 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Ikena Oncology, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 9 | 16 | 31 | 9 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 9 | 16 | 31 | 9 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 85 | 87 | 65 | 54 | 0 |
Income After Depreciation & Amortization | -75 | -71 | -34 | -45 | 0 |
Non-Operating Income | 7 | 2 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -68 | -69 | -34 | -44 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -68 | -69 | -34 | -44 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -68 | -69 | -34 | -44 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -76 | -70 | -34 | -44 | 0 |
Depreciation & Amortization (Cash Flow) | -1 | 1 | 1 | 0 | NA |
Income After Depreciation & Amortization | -75 | -71 | -34 | -45 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 41.74 | 36.19 | 27.98 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.63 | -1.90 | -1.22 | NA | NA |
Diluted Net EPS (GAAP) | -1.63 | -1.90 | -1.22 | NA | NA |
Fiscal Year end for Ikena Oncology, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.66 | 1.19 | 2.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.66 | 1.19 | 2.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 18.23 | 22.56 | 20.68 | 20.49 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -18.23 | -21.90 | -19.49 | -18.49 |
Non-Operating Income | NA | 2.11 | 2.26 | 2.16 | 1.38 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -16.12 | -19.65 | -17.34 | -17.12 |
Income Taxes | NA | 0.03 | -0.16 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -16.15 | -19.49 | -17.34 | -17.12 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -16.15 | -19.49 | -17.34 | -17.12 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 48.26 | 47.81 | 43.44 | 39.29 |
Diluted EPS Before Non-Recurring Items | NA | -0.28 | -0.41 | -0.40 | -0.44 |
Diluted Net EPS (GAAP) | NA | -0.33 | -0.40 | -0.40 | -0.44 |